This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Rozerem

Takeda Pharmaceutical Company Ltd

Drug Names(s): ramelteon (oral), TAK-375

Description: Rozerem stimulates the melatonin MT1 and MT2 receptors, which are thought to be involved in the sleep-wake cycle.

Takeda is also developing the sublingual formulation of ramelteon, TAK-375SL.

Deal Structure: TAP Pharmaceuticals (Takeda/Abott)
TAP Pharmaceutical Products (TAP), a joint venture between Takeda and Abbott, co-promotes Rozerem in the U.S.

In March 2008, Takeda Pharmaceutical and Abbott concluded their TAP Pharmaceutical Products (TAP) joint venture.

Takeda and Meiji
In September 2014, Meiji Seika and Takeda announced that the two companies have finalized a co-promotion agreement in Japan regarding ROZEREM, a product for treatment of insomnia that Takeda currently manufactures and markets. In accordance with this agreement, Meiji will commence promotional activities for ROZEREM on October 1, 2014, mainly targeting psychiatric institutions covered by MRs fully dedicated to the CNS field. Takeda will continue its current promotional activities which target all medical institutions, including psychiatric institutions. The companies refrain from disclosing the details of this co-promotion agreement, including financials terms and conditions.

Partners: Meiji Seika Pharma Co., Ltd


Rozerem News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug